Autolus publishes corporate presentation on next-generation programmed T-cell therapies, led by AUCATZYL franchise expansion
Reuters2026/08/18 16:17Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
- Autolus highlighted AUCATZYL momentum, reporting 1H 2026 net product revenue of $71.9 million.
- FY 2026 net product revenue guidance raised to $140-$150 million.
- Manufacturing success rate reported above 90%, citing no capacity constraints on product delivery.
- FELIX pivotal data cited a 77% remission rate (CR/CRi), 2% grade ≥3 CRS, 7% grade ≥3 ICANS; median response 42.6 months.
- Pipeline priorities include pivotal Phase 2 trials in lupus nephritis and pediatric ALL, with Phase 1 development in progressive multiple sclerosis.
Disclaimer:
This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autolus Therapeutics plc published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley cuts Mercedes-Benz voting rights stake to 5.12%
Reuters•2026/08/18 17:24
Uber's Expansion With AV Partners Seen Boosting Confidence -- Market Talk
Dow Jones•2026/08/18 17:23
Macy's Traffic Shows Signs of Stabilizing, Report Says -- Market Talk
Dow Jones•2026/08/18 17:22
Kona BidCo raises Zalaris stake to 87.34% after buying 2,337 shares at NOK 100 apiece
Reuters•2026/08/18 17:18
